Iressa shows promise in advanced NSCLC

Published: 2006-06-22 06:57:00

Updated: 2006-06-22 06:57:00

Follow-up study results show that Iressa (gefinitib) is effective in the treatment of advanced non-small cell lung cancer (NSCLC) in Korean patients, according to the Korean Cancer Study Group.

Prof. Kang Jin-hyung of Kangnam St. Mary hospital said that at least 50 percent of reduction in tumo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK